Acelyrin's $540M IPO amidst quiet biotech market
TL;DR Summary
California-based drug developer Acelyrin has gone public in one of the largest biotech IPOs since 2021, raising $540m. However, industry insiders say the IPO is an "N of 1" as over 50 biotechs are still waiting for their moment on the markets. The biotech industry is facing macro challenges such as high-interest rates, a banking crisis, and the war in Ukraine, which are hampering the capital market.
- Acelyrin goes public in $540M IPO amid quiet biotech market – Endpoints News Endpoints News
- SLRN Stock IPO: When Does Acelyrin Go Public? What Is the Acelyrin IPO Price Range? InvestorPlace
- Kenvue, Acelyrin Go Public This Week. Don't Expect a Flood of Biotech IPOs. Barron's
- Acelyrin sets out massive $540M upsized IPO FierceBiotech
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
6 min
vs 7 min read
Condensed
95%
1,349 → 67 words
Want the full story? Read the original article
Read on Endpoints News